Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

Hannover Medical School, Hannover, Germany

Elmar Jaeckel is a medical doctor in the Department of Gastroenterology, Hepatology & Endocrinology at the Hannover Medical School, Hannover, Germany. He received his training in Hamburg, Germany; Yale New Haven, New Haven, CT, USA; the University of California San Diego, CA, USA; the University of Edinburgh, Edinburgh, UK; and the University of Sydney, Sydney, Australia. Dr Jaeckel spent 4 years as a postdoctoral fellow at the Joslin Diabetes Center of the Harvard Medical School, Boston, MA, USA. He is the attending endocrinologist and diabetologist at the Hannover Medical School.


Dr Jaeckel’s working group, Immune Tolerance, aims to establish immune tolerance in type 1 diabetes and after biological beta-cell replacement. For this purpose, he is developing new cell and gene therapy approaches. Dr Jaeckel is involved in pursuing islet xenotransplantation in Germany. He is also studying non-alcoholic steatohepatitis (NASH) in animal models and patient material and is developing incretin-based therapies for NASH.